Abstract: The disclosure provides, inter alia, safe and environmentally-friendly methods, such as flow chemistry, to synthesize isocyanates, such as methylene diphenyl diisocyanate, toluene diisocyanate, hexamethylene diisocyanate, isophorone diisocyanate, and tetramethylxylene diisocyanate.

Abstract: Disclosed herein, inter alia, are methods of making polyketide compounds.

Abstract: Disclosed herein, inter alia, are fatty acid and polymer compositions and methods of making the same.

Abstract: Provided herein, inter alia, are splice modulator compounds. The compounds include optically pure, stereospecific analogs of FD-895. The methods provided herein allow, for example, for scalable preparation of said compounds, and further allow, for example, use of said compounds for inhibiting spliceosome activity.

Abstract: The disclosure is directed to a method of engineering a heterologous thioesterase (TE) enzyme to interact with endogenous acyl-ACP proteins in order to produce molecules of interest in a bacterial host. The method can identify amino acids at the binding interface between the heterologous TE and the endogenous acyl-ACP that can be substituted so that the heterologous TE can better interact with the endogenous acyl-ACP. Mutant heterologous TE enzymes with improved interactions with the endogenous acyl-ACP are also provided.

Abstract: Provided herein, inter alia, is a modular-functional technology for the expression of a functional heterologous polyketide synthases (PKS) system in a photosynthetic cyanobacteria.

Abstract: There are provided inter alia stable anti-cancer compounds and splice modulators and methods of synthesis and use thereof.

Abstract: Provided herein, inter alia, is a modular-functional technology for the expression of a functional heterologous polyketide synthases (PKS) system in a photosynthetic cyanobacteria.

Abstract: A halogenation system, a method of halogenating a substrate, and halogenated compounds are provided. The halogenation system includes PltM immobilized on a solid support. The system may include one or more additional enzymes immobilized on the solid support. The method of halogenating a substrate includes running the substrate and a reaction solution through the halogenation system including PltM immobilized on a solid support. The halogenated compounds include 4,6-diCl-3, 4,6-diCl-8, 2,4-diCl-9, 2,6-diCl-11, 3,5-diCl-15, 4,6-diCl-16, 4,6-diCl-18, 4-Cl-23, and/or 4,6-diBr-3.

Abstract: There are provided inter alia stable anti-cancer compounds and splice modulators and methods of synthesis and use thereof.

Abstract: There are provided, inter alia, methods and compositions for diagnosis and treatment of acute myeloid leukemia (AML), secondary acute myeloid leukemia (sAML), and age-related diseases.

Abstract: There are provided, inter alia, methods and compositions for diagnosis and treatment of acute myeloid leukemia (AML), secondary acute myeloid leukemia (sAML), and age-related diseases.

Abstract: Provided herein, inter alia, are methods and compositions for removing a phosphopantethiene analog moiety from an ACP-phosphopantetheine conjugate thereby providing Apo-ACP proteins.

Abstract: Provided herein, inter alia, are anticancer polyketides. The uses of the polyketides described herein include treatment of cancer, for example, through regulation of the spliceosome and detection of spliceosome inhibition.

Abstract: Provided herein, inter alia, are methods and compositions for removing a phosphopantethiene analogue moiety from an ACP-phosphopantetheine conjugate thereby providing Apo-ACP proteins.

Abstract: Provided herein, inter alia, are anticancer polyketides. The uses of the polyketides described herein include treatment of cancer, for example, through regulation of the spliceosome and detection of spliceosome inhibition.

Abstract: The present disclosure relates generally to compositions and methods for treating cancer. In some aspects, novel spirohexenolides and methods of using and producing them are described.

Abstract: The present disclosure relates generally to compositions and methods for treating cancer. In some aspects, novel spirohexenolides and methods of using and producing them are described.

Abstract: Methods to generate analogs of coenzyme A in vivo are disclosed. The methods to generate analogs of coenzyme A in a cell comprise reacting pantetheine or a derivative thereof with a reporter to form labeled pantetheine or a derivative thereof, contacting the cell with the labeled pantetheine or derivative thereof such that the labeled pantetheine or derivative thereof enters the cell, phosphorylating the labeled pantetheine or derivative thereof to form phosphopantetheine or a derivative thereof, adenylating the labeled phosphopantetheine or derivative thereof to form a labeled dephosphoCoenzyme A or derivative thereof, and phosphorylating the 3?-hydroxyl of the labeled dephosphoCoenzyme A or derivative thereof to form a labeled coenzyme A analog or derivative thereof.

Abstract: Methods to generate analogs of coenzyme A in vivo are disclosed. The methods to generate analogs of coenzyme A in a cell comprise reacting pantetheine or a derivative thereof with a reporter to form labeled pantetheine or a derivative thereof, contacting the cell with the labeled pantetheine or derivative thereof such that the labeled pantetheine or derivative thereof enters the cell, phosphorylating the labeled pantetheine or derivative thereof to form phosphopantetheine or a derivative thereof, adenylating the labeled phosphopantetheine or derivative thereof to form a labeled dephosphoCoenzyme A or derivative thereof, and phosphorylating the 3?-hydroxyl of the labeled dephosphoCoenzyme A or derivative thereof to form a labeled coenzyme A analog or derivative thereof.